Cargando…

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience

Detalles Bibliográficos
Autores principales: Talreja, Vikas T., Noronha, Vanita, Patil, Vijay M., Joshi, Amit, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956572/
https://www.ncbi.nlm.nih.gov/pubmed/31956629
http://dx.doi.org/10.4103/sajc.sajc_364_19
_version_ 1783487173594447872
author Talreja, Vikas T.
Noronha, Vanita
Patil, Vijay M.
Joshi, Amit
Prabhash, Kumar
author_facet Talreja, Vikas T.
Noronha, Vanita
Patil, Vijay M.
Joshi, Amit
Prabhash, Kumar
author_sort Talreja, Vikas T.
collection PubMed
description
format Online
Article
Text
id pubmed-6956572
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-69565722020-01-17 Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience Talreja, Vikas T. Noronha, Vanita Patil, Vijay M. Joshi, Amit Prabhash, Kumar South Asian J Cancer Letter to the Editor Wolters Kluwer - Medknow 2020 /pmc/articles/PMC6956572/ /pubmed/31956629 http://dx.doi.org/10.4103/sajc.sajc_364_19 Text en Copyright: © 2019 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Letter to the Editor
Talreja, Vikas T.
Noronha, Vanita
Patil, Vijay M.
Joshi, Amit
Prabhash, Kumar
Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
title Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
title_full Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
title_fullStr Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
title_full_unstemmed Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
title_short Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
title_sort lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: indian experience
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956572/
https://www.ncbi.nlm.nih.gov/pubmed/31956629
http://dx.doi.org/10.4103/sajc.sajc_364_19
work_keys_str_mv AT talrejavikast lorlatinibinanaplasticlymphomakinasepositivenonsmallcelllungcancerindianexperience
AT noronhavanita lorlatinibinanaplasticlymphomakinasepositivenonsmallcelllungcancerindianexperience
AT patilvijaym lorlatinibinanaplasticlymphomakinasepositivenonsmallcelllungcancerindianexperience
AT joshiamit lorlatinibinanaplasticlymphomakinasepositivenonsmallcelllungcancerindianexperience
AT prabhashkumar lorlatinibinanaplasticlymphomakinasepositivenonsmallcelllungcancerindianexperience